EV/Sales Ratio: 7.82x
Is the EV/Sales ratio high or low?
The EV/Sales ratio of 7.82x is in line with its 5-year average of 8.27x, around the middle of its 5-year range (4.79x–13.95x).
As of Saturday, June 27, 2026. 24.82% above its 12-month average of 6.26x.
WST EV/Sales Ratio Chart
WST Average EV/Sales Ratio Chart
WST Current vs Average EV/Sales Ratio Chart
WST EV/Sales Ratio Metrics
EV/SALES RATIO
7.82x
EV/SALES RATIO AVG TTM
6.26x
EV/SALES RATIO AVG 3Y
7.54x
EV/SALES RATIO AVG 5Y
8.27x
EV/SALES RATIO AVG 10Y
7.19x
EV/SALES RATIO AVG 15Y
5.58x
EV/SALES RATIO AVG 20Y
4.60x
CURRENT VS TTM AVG
+24.82%
CURRENT VS 3Y AVG
+3.69%
CURRENT VS 5Y AVG
-5.49%
CURRENT VS 10Y AVG
+8.79%
CURRENT VS 15Y AVG
+40.13%
CURRENT VS 20Y AVG
+70.05%
WST Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| West Pharmaceutical Services, Inc. (WST) | $24.79B | 7.82x | 6.26x | 7.54x | 8.27x |
| Waters Corporation (WAT)vs › | $24.41B | 9.51x | 7.11x | 7.18x | 7.32x |
| Mettler-Toledo International Inc. (MTD)vs › | $25.54B | 6.80x | 7.32x | 7.49x | 8.14x |
| Quest Diagnostics Incorporated (DGX)vs › | $23.23B | 2.67x | 2.52x | 2.37x | 2.22x |
| BioNTech SE (BNTX)vs › | $23.07B | 3.63x | 4.13x | 3.74x | 3.34x |
| United Therapeutics Corporation (UTHR)vs › | $23.03B | 7.74x | 6.60x | 5.75x | 5.79x |
| Moderna, Inc. (MRNA)vs › | $26.69B | 11.67x | 6.25x | 5.11x | 6.61x |
| Incyte Corporation (INCY)vs › | $22.73B | 3.75x | 3.34x | 3.05x | 3.67x |
| DexCom, Inc. (DXCM)vs › | $27.07B | 5.79x | 6.53x | 10.07x | 13.74x |
| Labcorp Holdings Inc. (LH)vs › | $22.26B | 2.03x | 2.09x | 2.00x | 1.88x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EV/Sales Ratio FAQ
- What is the EV/Sales ratio for West Pharmaceutical Services, Inc. (WST)?
- The EV/Sales ratio for WST stock is 7.82x.
- Is West Pharmaceutical Services, Inc.'s EV/Sales ratio high or low?
- The EV/Sales ratio of 7.82x is in line with its 5-year average of 8.27x, around the middle of its 5-year range (4.79x–13.95x).
- What is the TTM average EV/Sales ratio for West Pharmaceutical Services, Inc. (WST)?
- The TTM average EV/Sales ratio for WST stock is 6.26x.
- What is the 3Y average EV/Sales ratio for West Pharmaceutical Services, Inc. (WST)?
- The 3Y average EV/Sales ratio for WST stock is 7.54x.
- What is the 5Y average EV/Sales ratio for West Pharmaceutical Services, Inc. (WST)?
- The 5Y average EV/Sales ratio for WST stock is 8.27x.
- What is the 10Y average EV/Sales ratio for West Pharmaceutical Services, Inc. (WST)?
- The 10Y average EV/Sales ratio for WST stock is 7.19x.
- What is the 15Y average EV/Sales ratio for West Pharmaceutical Services, Inc. (WST)?
- The 15Y average EV/Sales ratio for WST stock is 5.58x.
- What is the 20Y average EV/Sales ratio for West Pharmaceutical Services, Inc. (WST)?
- The 20Y average EV/Sales ratio for WST stock is 4.60x.
WST EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-26 | 7.82x |
| 2026-06-25 | 7.73x |
| 2026-06-24 | 7.59x |
| 2026-06-23 | 7.50x |
| 2026-06-22 | 7.35x |
| 2026-06-18 | 7.31x |
| 2026-06-17 | 7.21x |
| 2026-06-16 | 7.35x |
| 2026-06-15 | 7.39x |
| 2026-06-12 | 7.33x |
| 2026-06-11 | 7.36x |
| 2026-06-10 | 7.38x |
| 2026-06-09 | 7.46x |
| 2026-06-08 | 7.12x |
| 2026-06-05 | 7.01x |
| 2026-06-04 | 7.07x |
| 2026-06-03 | 7.05x |
| 2026-06-02 | 6.95x |
| 2026-06-01 | 7.05x |
| 2026-05-29 | 7.19x |
| 2026-05-28 | 7.17x |
| 2026-05-27 | 6.97x |
| 2026-05-26 | 7.04x |
| 2026-05-22 | 7.05x |
| 2026-05-21 | 7.04x |
| 2026-05-20 | 6.80x |
| 2026-05-19 | 6.77x |
| 2026-05-18 | 6.78x |
| 2026-05-15 | 6.75x |
| 2026-05-14 | 6.69x |
| 2026-05-13 | 6.73x |
| 2026-05-12 | 6.95x |
| 2026-05-11 | 7.18x |
| 2026-05-08 | 7.26x |
| 2026-05-07 | 7.18x |
| 2026-05-06 | 6.96x |
| 2026-05-05 | 6.90x |
| 2026-05-04 | 6.68x |
| 2026-05-01 | 6.70x |
| 2026-04-30 | 6.63x |
| 2026-04-29 | 6.58x |
| 2026-04-28 | 6.50x |
| 2026-04-27 | 6.73x |
| 2026-04-24 | 6.82x |
| 2026-04-23 | 6.90x |
| 2026-04-22 | 6.34x |
| 2026-04-21 | 6.34x |
| 2026-04-20 | 6.42x |
| 2026-04-17 | 6.32x |
| 2026-04-16 | 6.23x |
| 2026-04-15 | 6.15x |
| 2026-04-14 | 6.18x |
| 2026-04-13 | 6.00x |
| 2026-04-10 | 5.92x |
| 2026-04-09 | 5.96x |
| 2026-04-08 | 6.14x |
| 2026-04-07 | 5.98x |
| 2026-04-06 | 5.92x |
| 2026-04-02 | 5.87x |
| 2026-04-01 | 5.82x |
| 2026-03-31 | 5.78x |
| 2026-03-30 | 5.65x |
| 2026-03-27 | 5.60x |
| 2026-03-26 | 5.72x |
| 2026-03-25 | 5.69x |
| 2026-03-24 | 5.65x |
| 2026-03-23 | 5.56x |
| 2026-03-20 | 5.45x |
| 2026-03-19 | 5.53x |
| 2026-03-18 | 5.50x |
| 2026-03-17 | 5.51x |
| 2026-03-16 | 5.53x |
| 2026-03-13 | 5.42x |
| 2026-03-12 | 5.31x |
| 2026-03-11 | 5.48x |
| 2026-03-10 | 5.38x |
| 2026-03-09 | 5.71x |
| 2026-03-06 | 5.66x |
| 2026-03-05 | 5.63x |
| 2026-03-04 | 5.73x |
| 2026-03-03 | 5.79x |
| 2026-03-02 | 5.79x |
| 2026-02-27 | 5.86x |
| 2026-02-26 | 5.74x |
| 2026-02-25 | 5.71x |
| 2026-02-24 | 5.65x |
| 2026-02-23 | 5.62x |
| 2026-02-20 | 5.55x |
| 2026-02-19 | 5.61x |
| 2026-02-18 | 5.72x |
| 2026-02-17 | 5.60x |
| 2026-02-13 | 5.93x |
| 2026-02-12 | 5.76x |
| 2026-02-11 | 5.82x |
| 2026-02-10 | 5.76x |
| 2026-02-09 | 5.89x |
| 2026-02-06 | 5.89x |
| 2026-02-05 | 5.47x |
| 2026-02-04 | 5.60x |
| 2026-02-03 | 5.46x |
| 2026-02-02 | 5.61x |
| 2026-01-30 | 5.46x |
| 2026-01-29 | 5.50x |
| 2026-01-28 | 5.57x |
| 2026-01-27 | 5.69x |
| 2026-01-26 | 5.71x |
| 2026-01-23 | 5.59x |
| 2026-01-22 | 5.86x |
| 2026-01-21 | 6.04x |
| 2026-01-20 | 5.93x |
| 2026-01-16 | 6.15x |
| 2026-01-15 | 6.62x |
| 2026-01-14 | 6.52x |
| 2026-01-13 | 6.44x |
| 2026-01-12 | 6.47x |
| 2026-01-09 | 6.53x |
| 2026-01-08 | 6.52x |
| 2026-01-07 | 6.60x |
| 2026-01-06 | 6.65x |
| 2026-01-05 | 6.61x |
| 2026-01-02 | 6.55x |
| 2025-12-31 | 6.52x |
| 2025-12-30 | 6.56x |
| 2025-12-29 | 6.53x |
| 2025-12-26 | 6.50x |
| 2025-12-24 | 6.56x |
| 2025-12-23 | 6.58x |
| 2025-12-22 | 6.51x |
| 2025-12-19 | 6.46x |
| 2025-12-18 | 6.36x |
| 2025-12-17 | 6.38x |
| 2025-12-16 | 6.31x |
| 2025-12-15 | 6.44x |
| 2025-12-12 | 6.34x |
| 2025-12-11 | 6.46x |
| 2025-12-10 | 6.32x |
| 2025-12-09 | 6.30x |
| 2025-12-08 | 6.37x |
| 2025-12-05 | 6.64x |
| 2025-12-04 | 6.68x |
| 2025-12-03 | 6.74x |
| 2025-12-02 | 6.47x |
| 2025-12-01 | 6.50x |
| 2025-11-28 | 6.57x |
| 2025-11-26 | 6.57x |
| 2025-11-25 | 6.66x |
| 2025-11-24 | 6.49x |
| 2025-11-21 | 6.42x |
| 2025-11-20 | 6.10x |
| 2025-11-19 | 6.10x |
| 2025-11-18 | 6.16x |
| 2025-11-17 | 6.21x |
| 2025-11-14 | 6.19x |
| 2025-11-13 | 6.32x |
| 2025-11-12 | 6.49x |
| 2025-11-11 | 6.57x |
| 2025-11-10 | 6.53x |
| 2025-11-07 | 6.42x |
| 2025-11-06 | 6.52x |
| 2025-11-05 | 6.72x |
| 2025-11-04 | 6.80x |
| 2025-11-03 | 6.63x |
| 2025-10-31 | 6.69x |
| 2025-10-30 | 6.60x |
| 2025-10-29 | 6.75x |
| 2025-10-28 | 6.72x |
| 2025-10-27 | 6.81x |
| 2025-10-24 | 7.06x |
| 2025-10-23 | 7.29x |
| 2025-10-22 | 6.74x |
| 2025-10-21 | 6.80x |
| 2025-10-20 | 6.69x |
| 2025-10-17 | 6.59x |
| 2025-10-16 | 6.50x |
| 2025-10-15 | 6.40x |
| 2025-10-14 | 6.35x |
| 2025-10-13 | 6.39x |
| 2025-10-10 | 6.37x |
| 2025-10-09 | 6.41x |
| 2025-10-08 | 6.52x |
| 2025-10-07 | 6.47x |
| 2025-10-06 | 6.52x |
| 2025-10-03 | 6.63x |
| 2025-10-02 | 6.65x |
| 2025-10-01 | 6.61x |
| 2025-09-30 | 6.38x |
| 2025-09-29 | 6.33x |
| 2025-09-26 | 6.36x |
| 2025-09-25 | 6.19x |
| 2025-09-24 | 6.32x |
| 2025-09-23 | 6.10x |
| 2025-09-22 | 6.13x |
| 2025-09-19 | 6.20x |
| 2025-09-18 | 6.20x |
| 2025-09-17 | 6.24x |
| 2025-09-16 | 6.28x |
| 2025-09-15 | 6.26x |
| 2025-09-12 | 6.17x |
| 2025-09-11 | 6.42x |
| 2025-09-10 | 6.21x |
| 2025-09-09 | 6.13x |
| 2025-09-08 | 6.16x |
| 2025-09-05 | 6.10x |
| 2025-09-04 | 6.02x |
| 2025-09-03 | 6.05x |
| 2025-09-02 | 5.93x |
| 2025-08-29 | 6.00x |
| 2025-08-28 | 5.97x |
| 2025-08-27 | 5.98x |
| 2025-08-26 | 5.94x |
| 2025-08-25 | 6.01x |
| 2025-08-22 | 6.03x |
| 2025-08-21 | 5.90x |
| 2025-08-20 | 5.99x |
| 2025-08-19 | 6.01x |
| 2025-08-18 | 5.91x |
| 2025-08-15 | 5.99x |
| 2025-08-14 | 5.99x |
| 2025-08-13 | 5.99x |
| 2025-08-12 | 5.83x |
| 2025-08-11 | 5.84x |
| 2025-08-08 | 5.86x |
| 2025-08-07 | 5.85x |
| 2025-08-06 | 5.77x |
| 2025-08-05 | 5.81x |
| 2025-08-04 | 5.79x |
| 2025-08-01 | 5.82x |
| 2025-07-31 | 5.82x |
| 2025-07-30 | 6.06x |
| 2025-07-29 | 6.15x |
| 2025-07-28 | 6.27x |
| 2025-07-25 | 6.41x |
| 2025-07-24 | 6.80x |
| 2025-07-23 | 5.70x |
| 2025-07-22 | 5.48x |
| 2025-07-21 | 5.26x |
| 2025-07-18 | 5.28x |
| 2025-07-17 | 5.55x |
| 2025-07-16 | 5.62x |
| 2025-07-15 | 5.54x |
| 2025-07-14 | 5.62x |
| 2025-07-11 | 5.69x |
| 2025-07-10 | 5.74x |
| 2025-07-09 | 5.67x |
| 2025-07-08 | 5.52x |
| 2025-07-07 | 5.55x |
| 2025-07-03 | 5.57x |
| 2025-07-02 | 5.54x |
| 2025-07-01 | 5.57x |
| 2025-06-30 | 5.48x |
| 2025-06-27 | 5.48x |
| 2025-06-26 | 5.49x |
| 2025-06-25 | 5.54x |
| 2025-06-24 | 5.58x |
| 2025-06-23 | 5.43x |
| 2025-06-20 | 5.41x |
| 2025-06-18 | 5.46x |
| 2025-06-17 | 5.46x |
| 2025-06-16 | 5.62x |
| 2025-06-13 | 5.56x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Eric Green